Drug Trial Radar · NCT06239194
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
330
Planned (sponsor's estimate)
Start
Jun 12, 2024
Primary completion
Aug 2028
Study completion Feb 2029
Sponsor
- Lead sponsor
- ModeX Therapeutics, An OPKO Health CompanyIndustry
- Sponsor type
- Industry
- First posted
- Feb 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Conditions
- Biliary Tract Cancer
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Endometrial Cancer
- Esophageal Cancer
- Gastric Cancer
- GastroEsophageal Cancer
- Head and Neck Cancer
- Hepatocellular Cancer
- Non-small Cell Lung Cancer
- Pancreatic Cancer
- Prostate Cancer
- Rectal Cancer
- Renal Cancer
- Thyroid Cancer
- Urothelial Carcinoma (UC)
- Cholangiocarcinoma
- Mesothelioma
- Gallbladder Cancer
- Ovarian Cancer
Interventions
MDX2001Drug
MDX2001 intravenous infusion or subcutaneous (SC) injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All Phases: Adverse events (AEs)Time frame: Baseline until end of study, up to approximately 9 months
- Phase 1b and Phase 2a: Objective response rate of MDX2001Time frame: From date of enrollment until the end of treatment, up to approximately 6 months
- Phase 1: Recommended Phase 2 dose (RP2D)Time frame: Baseline until end of study, up to approximately 9 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Sarah Cannon Research Institute
Denver, Colorado · Recruiting
Sylvester Comprehensive Cancer Center - University of Miami Health System
Miami, Florida · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.